Provenienza dei contatti di primo grado di Antonio Casini
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Alia Therapeutics Srl
 Alia Therapeutics Srl BiotechnologyHealth Technology Alia Therapeutics Srl engages in experimental research activities in the field of biotechnology. It specializes in the identification of new technologies for genome modification. The company was founded by Gianluca Petris, Antonio Casini, and Anna Cereseto and is headquartered in Trento, Italy.
3
| Holding Company | Biotechnology | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Antonio Casini tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| CTI BIOPHARMA CORP. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Pisa | College/University | Undergraduate Degree | |
BiovelocITA Srl
 BiovelocITA Srl Investment ManagersFinance Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy. | Investment Managers | Founder | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
Nephris Srl
 Nephris Srl Miscellaneous Commercial ServicesCommercial Services Nephris Srl provides pre-clinical and research services for kidney diseases. The company is based in Milan, Italy. The Italian company was founded in 2021 by Paolo Fiorina, Francesca D'Addio. The CEO is Maria Gabriella Camboni. | Miscellaneous Commercial Services | Chairman | |
| Alexandria University | College/University | Doctorate Degree | |
| Rush University | College/University | Graduate Degree | |
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Biotechnology | Chief Executive Officer | |
| University of Perugia | College/University | Graduate Degree |
Statistiche
Distribuzione geografica
| Italia | 7 |
| Stati Uniti | 5 |
| Francia | 2 |
Settori
| Health Technology | 6 |
| Consumer Services | 5 |
| Finance | 3 |
| Commercial Services | 2 |
Posizioni
| Chairman | 4 |
| Founder | 4 |
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 2 |
| President | 2 |
Contatti più connessi
| Insiders | |
|---|---|
| Silvano Spinelli | 8 |
| Adel Nada | 5 |
| Letizia Goretti | 2 |
- Borsa valori
- Insiders
- Antonio Casini
- Connessioni Società
